BioCorRx (OTCQB: BICX) is the owner and creator of an innovative addiction treatment program used by a network of independent treatment centers to improve the lives of their patients struggling with alcohol and opioid addictions. The BioCorRx® Recovery Program leverages an innovative, two-pronged approach that addresses the underlying physical and behavioral issues associated with these addictions. The first half of this approach relies on a highly effective, proprietary implant formulation of the FDA-approved medication naltrexone, for which BioCorRx holds worldwide license rights (excluding Australia and New Zealand). The second half focuses on a modular counseling program coupled with overlapping peer support that is tailored specifically for those afflicted with alcohol and opioid addictions, helping to prepare them both physically and mentally for a life without these often dangerous substances.

America’s opioid epidemic is an increasingly treacherous issue that affects millions of people across the country. Per data from the Centers for Disease Control and Prevention, more than half a million people in the United States died from drug overdose from 2000 to 2015. Of those, more than 60 percent were linked to an opioid. Likewise, deaths from prescription opioids have more than quadrupled since 1999, driven by a nearly identical spike in the amount of prescription opioids sold. The negative implications associated with this addiction include traumatic life events for the addicted and their loved ones, as well as monumental financial expense. A 2010 study conducted by the American Society of Addiction Medicine found that addiction costs an estimated $700 billion annually in the U.S. alone.

Treating this growing problem has proven difficult. In 2011, the Substance Abuse and Mental Health Services Administration reported that 23.5 million persons aged 12 or older, roughly 9.3 percent of the population, needed treatment for an illicit drug or alcohol abuse problem. Of those, only 11.2 percent received the vital treatment at a specialty facility. BioCorRx aims to close this gap by both operating specialty facilities to aid those in need and providing a more thorough treatment program that’s been shown to lower patient drop-out rates, due to reduced cravings, and increase compliance rates, through automatic medication delivery and discreet outpatient treatment options.

In recent months, BioCorRx, through its BioCorRx Pharmaceuticals subsidiary, has looked to continue building on this proven medication through the clinical development of BICX101, a sustained release, injectable naltrexone for the treatment of opioid and alcohol use disorders. In early April, the company announced that three different formulations of the drug candidate showed success in reaching 28 days of sustained release in its preclinical studies, including one with an injection volume of just one milliliter. Following this result, BioCorRx formally requested a pre-IND meeting with the U.S. Food and Drug Administration as it continues to conduct additional studies in order to compile more data points.

In a business update issued earlier this month, Lourdes Felix, CFO, COO and director of BioCorRx, noted the strength of the company’s balance sheet following a March equity financing of $940,000 with accredited investors, as well as an investment of $1.7 million from Alpine Creek Capital Partners. Capital stemming from these transactions is expected to allow BioCorRx to continue executing on its business plan, including completion of “a few rounds of preclinical studies of BICX101” and accelerated sales and marketing activities related to its BioCorRx Recovery Program.

A strong balance sheet isn’t the only aspect of BioCorRx’s growth strategy about which prospective shareholders should be particularly optimistic. On May 16, the company announced its submission of a listing application for the Nasdaq Capital markets. The move comes less than two months after OTC Markets Group (OTCQX: OTCM) welcomed BioCorRx to the OTCQB Venture Market, which it reserves for early-stage and developing companies that are current in their reporting and undergo an annual verification and management certification process. The company will be required to meet a number of Nasdaq listing requirements in order to complete the uplist, but CFO Felix noted that members of BioCorRx’s management team “look forward to the prospect of a NASDAQ listing,” which they anticipate will “enhance BioCorRx’s visibility in the investment community to a larger market and provide for a broader, more diverse base of shareholders.”

Addressing the growing opioid epidemic in the United States, as well as lingering alcohol addiction issues, represents both an urgent call to action and a sizable market opportunity for companies offering proven effective treatment options. BioCorRx, through its innovative non-addictive medication-assisted treatment (MAT) program and promising clinical pipeline, represents an opportunity for the investment community to participate in the resolution of this crisis while capitalizing on the growth prospects of a leading edge health care solutions company.

For more information, visit www.BioCorRx.com

Savvy investors study multiple factors to identify potential stock winners. Stock screeners scan thousands of companies for insights and data to discern uncommon opportunities. The criteria utilized in a stock screening system is obviously influenced by an individual’s investment proclivities such as high yield, value, growth or price momentum, however, most stock screening systems are typically hybrids with blended criteria reflecting individual preferences and incorporating more than one investment style. P/E ratios, near zero beta, increased dividends, revenue growth and market growth are all employed to sift through over 100,000 public companies around the world and the nearly 6,000 U.S. listed companies.

All markets are addicted to growth. Growth is the elixir that drives markets and share prices of individual companies higher, and every stock screening system includes growth measurement variables. Growth is a testament to value creation. Current and future growth are prime indicators of potential future performance of a company’s share price. When looking for growth, it makes sense to look closely at companies that are not only growing rapidly but also growing rapidly in a rapidly growing market. With compound annual growth estimated at nearly 60 percent, the CBD (cannabidiol) industry is arguably the fastest growing market in the world. In fact, just five months ago Forbes called the CBD industry, “The Cannabis Market That Could Grow 700% by 2020” (http://dtn.fm/5vDve). That kind of growth can change a portfolio.

Currently legal in 16 states with more expected to follow, CBD oil is non-psychoactive and considered to have a broad range of medical benefits. Derived from hemp or marijuana plants, CBD has shown varying degrees of efficacy in treating epilepsy, Alzheimer’s disease, cirrhosis, pain, anxiety and stress.

CBD is obviously an explosive market opportunity. However, an even greater market opportunity lies outside the U.S., with over two billion Chinese speaking people. Acceptance and use of CBD oil is a natural fit with holistic Eastern-based medicine and an immense potential revenue generator for ChineseInvestors.com (OTCQB: CIIX). With two billion Chinese speaking people as its target market, ChineseInvestors.com recently executed a first-to-market milestone by creating the world’s only Chinese language, cannabinoid-based, therapeutic health products online store, www.ChineseCBDoil.com.

Historically, this specialized investment services company with 100,000+ users provided real-time market commentary, analysis, and education-related information in the Chinese language, as well as offered consultation, advertising, and public relations services. Now, the 18-year-old company is at the forefront of marketing and selling hemp-based food and beverages and hemp-derived CBD to Chinese-speaking consumers worldwide through its online store.

A recent research report by Consilium Global Research (http://dtn.fm/SA4bH) projects ChineseInvestors.com to grow at a compound annual growth rate (CAGR) of approximately 100% through 2020. Consilium sees CIIX going through immense transformation this year as it pursues a larger stake in the global cannabis market. Before long, ChineseInvestors.com should pop up on multiple stock screeners, as it’s growing rapidly in a rapidly growing market.

For more information, visit the company’s website at www.ChineseInvestors.com

Let us hear your thoughts: ChineseInvestors.com, Inc. Message Board

Moxian, Inc. (NASDAQ: MOXC) has solidified its financial position as it competes in the massive Chinese sector of online-to-offline marketing. SeeThruEquity (http://nnw.fm/qTeF0) projected that the company could attain revenues of $24.1 million and net income of $4.5 million in FY 2018 as the O2O market is estimated to reach $48 billion in 1H17, according to investor materials provided by Moxian. One caveat to SeeThruEquity’s projections was for Moxian to demonstrate its ability to raise additional capital to finance its ambitious plans to compete in such a large market.

The high technology Shenzhen, China-based company netted some $8.5 million in an equity offering, at $4 per share, late in 2016 that resulted in its NASDAQ uplisting. In its SEC 10-Q filing of May 12, 2017, for the three-month period ended March 31, 2017 (http://nnw.fm/1xrKA), the firm additionally disclosed that it had received funds in a series of loans during the six months ended March 31, 2017.

The company is development stage and is building its infrastructure and staffing as it plans to execute its marketing strategy to take its two O2O mobile platforms from no charge to paid. Its Moxian+ is a paid business platform, with the firm’s immediate focus on converting its some 30,000 small market enterprise (SME) customers to paid. Similarly, it is attempting to convert its some 300,000 consumers on the Moxian User app from free to paid. Revenue streams foreseen by Moxian additionally include subscription revenues, transaction fees, mobile advertising, licensing fees, OEM and distribution charges.

SeeThruEquity was intrigued by the size of China’s O2O market and Moxian’s ambitious growth strategy, and it cautioned that the firm would require additional capital sources to finance and execute its strategy. The latest 10-Q by Moxian exhibited the firm’s ability to raise additional capital, enabling it to invest in more infrastructure and sales efforts.

During the six months ended March 31, 2017, the company received approximately $3.2 million from various related party loans and repaid a majority of all related party loans of approximately $5.6 million with IPO proceeds, the 10-Q filing said. Shenzhen Bayi Consulting Co., Limited and Moxian agreed to a series of loans aggregating $2.6 million unsecured, without interest or due on demand terms, to a subsidiary, Moxian Shenzhen. An earlier loan of $96,190 was made to Moxian by Bayi under the same terms. Vertical Venture Capital Group in this period made loans to subsidiary Moxian HK, with the same terms, in the aggregate of $553.8 million. Moxian HK partially repaid the loans as the company invested the funds internally.

Additionally, the SEC 10-Q stated that the company plans to bolster its future cash flows through additional related party financing and public and private placements.

For more information, visit www.Moxian.com

Looking to gain an advantageous foothold in the burgeoning medical marijuana market, India Globalization Capital, Inc. (NYSE MKT: IGC) is developing innovative cannabis-based combination therapies that have application for both humans and animals. The company’s focus is on treating pain, post-traumatic stress disorder (PTSD), chronic and terminal neurological and oncological diagnoses, cachexia, and other life-altering medical conditions.

IGC continues developing a portfolio of patent filings for phytocannabinoid-based treatments and has filed six patents to date. The company currently has three products in pre-clinical trials: IGC-501 for treatment of neuropathic pain in adult humans, IGC-502 for treatment of seizures in animals, and IGC-504 for treatment of cachexia in humans and animals.

Two of IGC’s patent filings, IGC-502 and IGC-505, are for combination therapies to treat seizures in dogs and cats, which represents a remarkably large market. Statistics show that between one percent and over five percent of dogs in the United States have some kind of seizure disorder. Certain dog breeds with hereditary epilepsy may have up to 15-20 percent incidence of seizures.

IGC’s novel therapy uses cannabinoid extracts in combination with other drugs to treat seizures in both dogs and cats, and this therapy has potential for application in humans, as well. The therapy can be administered through a variety of delivery technologies.

Operating on the belief that expanding cannabis legalization will create explosive demand for cannabinoid-based pharmaceutical therapies and related technologies and services, IGC is racing to be at the head of the pack and to be a first mover in the marijuana space by developing novel therapies, filing patent applications, and acquiring technologies from related industries that can cross over to cannabis as soon as permitted by federal law.

The company largely employs an outsourced model and has formed strategic alliances with doctors and scientists with expertise in central and peripheral nervous system disorders, the FDA process, and in pharmaceutical, nutraceutical and veterinarian trials. IGC also continues seeking information exchanges with medical cannabis dispensaries, doctors, research scientists, biotech companies, and medical and business professionals within the cannabinoid space, placing great value on collaborative research that can aid in the commercialization of products and in locating new ways to help patients — both human and animal — benefit from cannabinoids.

For more information, visit the company’s website at www.IGCinc.us

Let us hear your thoughts: India Globalization Capital, Inc. Message Board

Slowly but surely cannabis is losing the stigma that has plagued it for close to one hundred years. Even some who frown on its use for recreational purposes are willing to consider that there may be therapeutic benefits in extracts of the cannabis sativa plant and so, increasingly, cannabinoids are being investigated to determine their effectiveness to treat a variety of debilitating medical conditions. Cannabinoid pharma is emerging as an entirely new industry segment in pharmaceuticals, and, as it does so, one innovative research company is blazing a trail in this new market by creating a niche of its own. India Globalization Capital, Inc. (NYSE MKT: IGC) has created its own space in pharmaceuticals. The Bethesda, Maryland-based company is a first mover in “combination therapies” that merge cannabinoids with existing drugs to provide more effective remedies.

IGC is not only a first mover in combination therapies; the company is also a fast mover. To date, IGC has dispatched six provisional patent filings to the U.S. Patent and Trademark Office for the indications of pain, medical refractory epilepsy, seizures, cachexia and eating disorders. Together, the remedies for these conditions present huge market opportunity, and IGC’s current low valuation versus comparable cannabis companies represents an important alert for all investors in this burgeoning industry.

IGC-501 is being developed to combat pain. The pain market represents a significant component of the health care system, with The Journal of Pain reporting in September 2012 that the annual estimated national cost of pain ranges from $560 billion to $635 billion, a figure that exceeds the cost of treating all other priority health conditions. Also, a NetworkNewsWire report on data released by Transparency Market Research estimates the global pain management therapeutics market will have a 3.7 percent CAGR through 2024, to reach $83.0 billion (http://dtn.fm/cMh1z).

Chronic pain takes such an exacting toll on the nation’s health that the American Pain Society has recommended pain be characterized as a fifth ‘vital sign’, along with body temperature, pulse rate, respiratory rate and blood pressure. Pain treatment can save lives. Terminal illnesses are often accompanied by levels of pain so intense and difficult to treat that death seems preferable. In addition, arthritis has been particularly problematic for women, according to the Arthritis Foundation, which reports that since 1999 there has been a 22 percent increase in the number of women who attribute their disability to arthritis.

As awareness of the effects of chronic pain has grown, increasingly powerful drugs such as morphine, codeine, and hydrocodone are being prescribed. However, these opioids are treacherously addictive and their use is often subverted from pain relief, making their way into recreational use. According to the Centers for Disease Control (CDC), 29,000 Americans die every year from opioid-related overdoses. This alarming statistic shows the pressing need for less addictive analgesics like IGC-501.

IGC-503 tackles refractory epilepsy, which affects about 50 million in the U.S. alone. Refractory epilepsy refers to cases of epilepsy that are unresponsive to current medications. Also in the pipeline is IGC-504, intended for those who suffer from cachexia, known as wasting syndrome. About 1.3 million in the U.S. experience cachexia associated with cancer, multiple sclerosis (MS), Parkinson’s, HIV/AIDS and other devastating maladies. In addition, there is IGC-506, designed to combat eating disorders, which are said to affect about 30 million Americans (http://dtn.fm/2j6Pq). Two other patents, IGC-502 and IGC-505, are designed to treat epileptic seizures in dogs and cats.

On the release of its financial results for the third-quarter ended December 31, 2016, CEO Ram Mukunda stated, “In 2017, our goal is to accelerate the development of our cannabis-based therapy portfolio to support key indications such as pain, seizures, cachexia, PTSD, and depression. In tandem, we expect to initiate pre-clinical trials on IGC-501-pain, IGC-502-seizures and IGC-504-cachexia.”

For more information, visit the company’s website at www.IGCinc.us

Let us hear your thoughts: India Globalization Capital, Inc. Message Board

Net Element, Inc. (NASDAQ: NETE), for the three months ended March 31, 2017, enjoyed over 20% growth in revenues to $13,561,941, versus $11,261,059 for the same period a year earlier. North America Transaction Solutions, one of three operating segments of the global financial company, drove the firm’s growth, generating 81% of total sales compared to 70% during the same period of the prior year.

Net Element is a financial technology group that processes global transactions in an omni-channel environment in what is becoming a world of cashless transaction processing. The company processes electronic payments from point-of-sale and mobile devices.

Net revenues for the company were generated principally by payment processing fees in North America, where transactions jumped 40%, exhibiting organic growth, according to Zacks SCR Digest (http://nnw.fm/mTJ49). In 2016, Net Element recorded a 54% jump in North America to $42.1 million. That accounted for about 78% of total company sales for the year.

In the first quarter of 2017, North American Transactions increased their dominance of company sales — contributing 81% of Net Element sales. At the same time, the North American segment maintained its gross margin performance — contributing 14% for the first quarter of 2017 versus 15% during the same period of the prior year.

As the North American segment was cementing its hold on company revenues, mobile solutions continued their decline. In the first quarter of 2016, mobile solutions contributed 18% of company sales; that number fell to just 6% in the first quarter of 2017. Its sales dropped from $1,993,504 in 2016 down to $856,993 in the first quarter of 2017.

As a result of that performance, Oleg Firer, CEO of Net Element, said in a news release, “We are undertaking several strategic changes in the mobile solutions segment, which should yield results in the third-quarter of this year.”

SeeThruEquity, in an April 12, 2017, updated research report (http://nnw.fm/fFPV7), projects the company’s sales in FY 2017 at $62.9 million.

For more information, refer to www.NetElement.com

Although one of a number of substance abuse recovery and treatment centers in the southeastern coastal area of Florida, the Seastone of Delray – Drug Rehabilitation and Alcohol Treatment Center, owned and run by Ethema Health Corporation (OTCQB: GRST), is already standing out among its peers for the highly efficient individualized treatment options it offers its clients. Located in Delray Beach, which is often referred to as the rehab capital of America, Seastone offers a wide range of treatment programs of varying intensity, depending on each client’s needs. Unlike other centers, Seastone distinguishes itself by the attention paid to the individual client and family, making sure a highly detailed assessment is conducted before a specialized treatment plan is devised.

With a focus on customized treatment plans designed to help clients overcome their substance abuse issues permanently, Ethema Health Corporation’s center provides two forms of outpatient treatment: an intensive outpatient program, and a partial hospitalization program. Both approaches are built around the concepts of cognitive behavioral therapy and peer support, aiming to help clients see themselves and the world more clearly, and realize and accept that they’re facing an addiction issue, ultimately developing their stress management skills and self-esteem for long-term success.

Seastone’s drug and alcohol addiction treatment programs are divided into six stages, being structured for optimum recovery and accommodating any of their treatment plans. The six stages are:

Foundation – where clients get the highest level of direction and support to build a foundation for long-term recovery,
Discovery – where clients are taught to discard unhealthy ideas and habits gained during active addiction,
Creation – the development of sober, effective life skills,
Performance – helping clients gain more responsibility and independence,
Integration – clients continue to achieve more independence and responsibility by reintegrating in society,
Freedom – living full time in the community and dealing with real life issues.

Various treatment options and services are available for substance abuse treatment and recovery, ranging from psychiatric evaluation and drug addiction education to individual and group therapy, Eye Movement Desensitization and Reprocessing treatment, art therapy, yoga or qigong, and more. While it does not provide initial detox services, Seastone does work closely with local detox units to offer clients all the support they need and then transfer them to the facility for long-term treatment. The center’s detox programs are designed to follow and expand on the detoxification process begun in a medical setting, with the purpose of helping clients stay clean and sober for the long term. This stage of the program can begin only after the client is medically stable and free of all withdrawal symptoms.

Ethema Health Corporation’s methods are focused on getting concrete results and complete recovery from addiction, a fact also acknowledged by the Joint Commission on Accreditation of Healthcare Organizations. The worldwide organization has granted Seastone its Gold Seal of Approval®, which speaks to the professionalism and high-quality of services offered. Ethema’s unique efficiencies, together with its outstanding location, are seen as drivers of the company’s long-term operational and financial success

For more information about Ethema Health Corporation and Seastone, visit the substance abuse recovery facility online at www.seastonedrugrehab.com

Let us hear your thoughts: Ethema Health Corporation Message Board

Two recent Wall Street Journal articles reveal that labor pressures are mounting in the construction industry as hiring accelerates across the U.S. economy. The U.S. Labor Department recently reported that nonfarm payrolls rose by a seasonally adjusted 211,000 in April, and the unemployment rate fell to 4.4%, the lowest level in nearly a decade. Contractors across the country report significant shortages of electricians, carpenters, plumbers, and other skilled and semi-skilled laborers as the volume of building projects increases.

The shortage of skilled labor in many markets has forced contractors to boost pay scales, which has been a contributing factor to new home price increases over the past two years. Construction labor costs are currently rising an average of 4% to 5% annually, outpacing inflation, according to Anirban Basu, chief economist of the Associated Builders and Contractors. “The situation is going to get worse,” he said (http://dtn.fm/bm4Uu). It’s estimated that the construction industry presently needs 500,000 more skilled and semi-skilled workers, while another 600,000+ additional workers would be needed should the $1 trillion infrastructure bill proposed by the current administration be passed.

The skilled labor supply shortage isn’t expected to ease soon, as many top construction workers went to work for energy companies during the last building downturn and are now tending to oil rigs and building drilling platforms. ProBility Media Corp. (OTCQB: PBYA) is playing a major role in meeting this fast growing demand for job training and continuing education in the current economy. ProBility is one of the leading online providers of career advancement and training content for tradesmen and technical experts. By building the first full-service training and career advancement brand in the technical fields, the company is changing the landscape of the skilled trades training and certification industry.

ProBility is committed to preparing individuals with training, support, and continued education and teaches the skills needed to land and retain good jobs. The company, through strategic acquisitions, has also become one of the go-to sources for e-learning and training content, exam preparation, testing, certification, continuing education, and career advancement tools for both engineers and tradesmen. The broad collection of the company’s comprehensive educational programs is unparalleled, providing individuals and institutions with the skill sets needed to succeed. ProBility will continue to organically grow revenues from current operations while also strategically acquiring synergistic companies, thereby defragmenting and centralizing the skilled trades training marketplace.

The national unemployment rate for construction workers still remains in double digits, but economists note that figure includes both skilled and unskilled workers and finding a skilled worker not already working is increasingly rare. Finding highly specialized trade workers “is proving very, very difficult,” said James Bolger, director of operations at Colorado Concept Lighting Inc., a high-end electrical contractor that has sought for several months to double its staff of four electricians. “It’s almost like looking for a unicorn or jackalope…” (http://dtn.fm/PfZ0C).

ProBility is changing the search for skilled workers from fantasy to reality and is likely to reward investors along the way.

For more information, visit the company’s website at www.ProBilityMedia.com

Let us hear your thoughts: ProBility Media Corp. Message Board

While some investors still view the marijuana market as a new industry, the mammoth potential of the cannabis industry — both in the United States and worldwide — cannot be discounted. While marijuana has not yet been legalized in the U.S. at the federal level, 29 states as well as the District of Columbia have, so far, passed laws or initiatives to legalize or regulate it, and the industry has been growing at an unexpectedly high rate. Some savvy companies are safeguarding against the risk of violating present federal laws by capitalizing on the growth of the cannabis industry in a hands-off way, serving marijuana-related companies without touching the plant themselves. One such company is SinglePoint, Inc. (OTC: SING).

As discussed in a recent article (http://dtn.fm/msS5J), SinglePoint is building an acquisition portfolio of undervalued subsidiaries with a focus on innovative technologies. Within the marijuana industry, the company is pursuing different opportunities to build corporate value and maintain diversification. SingleSeed, SinglePoint’s marijuana vertical, is serving cannabis dispensaries that are currently hampered in their operations due to the present lack of banking options for businesses within the marijuana industry. SingleSeed is engaged in providing mobile payment processing solutions, text message marketing and business tools to marijuana dispensaries, with a long-term goal of building SingleSeed.com into a hub where dispensaries can purchase the products they need to conduct business. It is also planned that SingleSeed will offer consulting services for cannabis businesses that need assistance in getting a foothold and becoming successful in their strategies.

SinglePoint’s own strategy further involves the utilization of marijuana-related technology through its investment in Convectium, which is a successful equipment, branding and packaging solutions provider to the marijuana industry. Convectium has developed the very first cartridge and vape pen oil filling machines created for wholesale distribution to cannabis dispensaries. The 710Shark and 710Seal machines offered by Convectium, currently sold through the EquipCanna.com brand, can fill and package more than 100 cartridges or disposable vape pens in 30 seconds, revolutionizing the inefficient traditional method of hand-filling cartridges. Convectium additionally operates a consumer brand that includes HazeSticks and BlackoutX, with a customer reach that encompasses more than 52 countries.

SinglePoint recently signed a reseller agreement that enables the company to begin onboarding “high risk” merchant accounts, which includes more than 100 types of businesses. Cannabis businesses are currently counted among these high-risk business types, along with enterprises like auctions, gambling, vape pen sales, online gaming and others. Serving SinglePoint’s diversification strategy, this move will enable the company to provide payment solutions to cannabis businesses as soon as the marijuana industry becomes bankable. Offering payment solutions to various verticals in this way enlarges SinglePoint’s target market and paves the way for enormous success in catering to an underserved market.

For more information, visit the company’s website at www.SinglePoint.com

Let us hear your thoughts: SinglePoint, Inc. Message Board

China’s booming economy has delivered consumer product companies some of the world’s greatest growth opportunities over the last 20 years. However, the government recently lowered its official five-year annual GDP growth target to 6.5 percent, the slowest targeted growth since the 2008 global financial crisis. China’s economy is actually undergoing a structural transition. Consumption isn’t rising as fast as it did during peak boom years, but consumption growth is still on a staggering upward trajectory. China’s consumer economy is projected to expand by about half, to $6.5 trillion, by 2020. In fact, incremental Chinese consumer growth of over $2 trillion over the next three years would be equal to adding a consumer market larger than that of Germany today. Despite a slowing economy, China will remain one of the fastest growing consumer markets in the world for the foreseeable future.

Upward mobility and demographic forces are transforming the Chinese consumer markets. The meteoric rise of upper-middle-class households, a new generation of free spending tech savvy consumers and the powerful pull of e-commerce all promise immense new consumer opportunities.

Research by The Boston Consulting Group and AliResearch, the research arm of Alibaba, China’s largest e-commerce company (http://nnw.fm/2mt9X), found that these forces of change will profoundly reshape China’s economy and consumer market over the next several years. Consumers 35 or younger will account for 65% of growth, and e-commerce will become a far more important retail channel, driving 42% of total consumption growth, with 90% of that growth coming from mobile e-commerce. Companies will need a new playbook to capture the coming wave of growth, as the strategies of the past will no longer be relevant.

To capture the immense new opportunities in China’s changing consumer market, companies must be more strategic in targeting income segments, product categories, and retail channels. Companies also need a new set of strategies to take into account rapid shifts in the nature of consumption. Serving the businesses that feed the demand of the new Chinese consumer, Moxian, Inc. (NASDAQ: MOXC) is positioned to profit from this vast economic shift in China.

Moxian provides small- and medium-sized businesses cutting edge turnkey solutions to attract and maintain customers. The company’s strategy is to drive consumer traffic from online to their brick and mortar business customers. Moxian operates a social network platform which integrates social media and business into a single platform and offers products, features and services that appeal to consumers.

The company’s online platforms and mobile applications, the Moxian+ User app and the Moxian+ Business app, allow businesses to interface with both existing and new customers. These interactions provide each business the data to analyze consumer likes, dislikes and trends. Moxian’s platform gives businesses the ability to create, manage and promote individualized customer loyalty programs, targeted advertising campaigns and special promotions. These interactions between users and Moxian’s merchant clients give businesses the ability to study consumer behavior and tailor offerings to customers. Moxian is leveraging technology to drive business in the new Chinese consumer economy and offers an interesting opportunity to profit from this explosive growth.

For more information, visit www.Moxian.com